Data as of Aug 25, 2026 · Based on 3,181,687 AI responses across 10,525 prompts · See how Parse measures this
CHARM Therapeutics is developing next-generation menin inhibitors designed to address resistance seen with first-generation approaches in treating Acute Myeloid Leukemia. By targeting the menin-KMT2A interface, their structurally optimized inhibitors aim to reprogram leukemic cells rather than kill them.
Parse Score